A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO | |
Zeng, Xiaofeng; Wang, Yongfu; Jiang, Zhenyu; Zhang, Zhuoli; He, Lan; Zhang, Xiao; Lu, Xin; Liu, Xiumei; Xu, Jian; Huang, Cibo | |
2019 | |
会议名称 | ANNALS OF THE RHEUMATIC DISEASES |
会议日期 | 2019-06-01 |
页码 | 1140-1140 |
收录类别 | CPCI-S |
URL标识 | 查看原文 |
内容类型 | 会议论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6337259 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Zeng, Xiaofeng,Wang, Yongfu,Jiang, Zhenyu,et al. A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO[C]. 见:ANNALS OF THE RHEUMATIC DISEASES. 2019-06-01. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论